EP1993534A1 - Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity - Google Patents

Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity

Info

Publication number
EP1993534A1
EP1993534A1 EP07711778A EP07711778A EP1993534A1 EP 1993534 A1 EP1993534 A1 EP 1993534A1 EP 07711778 A EP07711778 A EP 07711778A EP 07711778 A EP07711778 A EP 07711778A EP 1993534 A1 EP1993534 A1 EP 1993534A1
Authority
EP
European Patent Office
Prior art keywords
light source
substance
oral cavity
range
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07711778A
Other languages
German (de)
French (fr)
Inventor
Olaf Schäfer
Daniela Krejci
Martin Werner Klarenaar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ELEXXION AG
Original Assignee
ELEXXION GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ELEXXION GmbH filed Critical ELEXXION GmbH
Publication of EP1993534A1 publication Critical patent/EP1993534A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to a method for treating in particular inflammatory disease states in the oral cavity by introducing a substance which can be activated by a light source.
  • Photodynamic therapy is understood to mean a photochemical process which has hitherto been used primarily in cancer therapy. By this term is generally understood a light-induced inactivation of cells, microorganisms or molecules. An active substance attaches to the cells to be controlled and is then activated by light
  • a modification of this principle is used in the control of microorganisms - the "antimicrobial photodynamic therapy" (APT) .
  • the aim is not the destruction of the body's own (tumor) cells, but the targeted control of local infections, the fight against microorganisms
  • the APT is based on the selective staining of the microorganisms by a so-called photosensitizer and the destruction of the germs by exposure to a suitable, matched to the photosensitizer light source.
  • a corresponding method is known from WO 01/87416 A1.
  • the microorganisms With the aid of the light-activatable substance, in particular a dye, the microorganisms are sensitized and / or stained and killed after irradiation with light of suitable wavelength and energy density:
  • the energy generated by means of an irradiation device, in particular a laser device is thus concentrated on the microorganisms and the equilibrium position reactions that occur in the unexposed state in the "normal" milieu are postponed and as a result the microorganisms are destroyed.
  • EP 0 637 976 B1 discloses the use of a photosensitizing substance or compound or photosensitizer (PS) in the manufacture of a medicament for use in disinfecting or sterilizing tissues of the oral cavity or a wound or lesion in the oral cavity Destroying disease-related microbes in a periodontal pocket, known in the region between the tooth and the gums. This involves contacting the tissue, the wound or the lesion with the photosensitizer, with the microbes associated with the disease receiving the photosensitizer. Irradiation of the tissue, wound or lesion with laser light is performed at a wavelength absorbing by the photosensitizer.
  • PS photosensitizing substance or compound or photosensitizer
  • the germ reduction of this combined dye and laser treatment is for different germs and Photosensitizer described in the form of solutions with, inter alia, methylene blue and toluidine blue, further showing the influence of the applied energy density.
  • the light sources used are HeNe lasers and GaAs lasers.
  • the object of the present invention is to provide a method of the above-mentioned. To develop a type in which a suitable drug is used, which is especially after a short time no longer detectable.
  • the substance contains the active ingredient indocyanine green and the spectrum of the light source emits significant proportions in the range of 700-1,000 nm.
  • Indocyanine Green is an infrared dye used in medical diagnostics and used under the name IR 125 as a laser dye. It is used as an intravenous diagnostic agent with a broad spectrum in the cardiovascular, microcirculation and liver function diagnostics application and especially in the measurement in the eye or the retina.
  • the main source of light is semiconductor lasers (diode lasers) or light emitting diodes (LEDs).
  • the used Light sources should preferably emit light with a wavelength in the range between 780-830 nm.
  • the output power of the light source is preferably in the range between 50 mW and 5,000 mW. This gives an irradiation dose of between 0.5 J-50 J at an exposure time of 10s-100s.
  • the light source When applying the light, the light source should be pulsed in the range between 1,000 and 50,000 Hz, preferably in the range between 10,000 Hz and 20,000 Hz.
  • the pause between two pulses may be longer than the pulse time.
  • the substance is administered in sterile dosage form. Furthermore, the substance can be added to other ingredients that positively influence inflammatory processes.
  • the substance in the form of a mouthwash solution remains in the oral cavity for a certain time and the exposure of the active substance to a light source takes place after rinsing out the active substance.
  • the exposure of the drug is via a device that contains the light source and is worn temporarily (e.g., during a break or overnight).
  • Another possibility is the introduction of the drug solution via a corresponding application device, such. a syringe in hard-to-reach areas, such as periodontal pockets or similar.

Abstract

In a process for treating disorders, especially inflammatory disorders, in the oral cavity by introducing a substance activable by a light source, the substance comprises the active ingredient indocyanine green and the spectrum of the light source emits significant proportions in the range of 700-1000 nm.

Description

VERWENDUNG VON LICHTAKTIVIERTEM INDOCYANINGRÜN ZUR BEHANDLUNG VON ENTZÜNDLICHEN KRANKHEITSZUSTÄNDEN IN DER MUNDHÖHLE USE OF LIGHT-ACTIVATED INDOCYANINGRENE FOR THE TREATMENT OF INFLAMMATORY DISEASE STATES IN THE MOUTH VALVE
Die Erfindung betrifft ein Verfahren zur Behandlung von insbesondere entzündlichem Krankheitszuständen in der Mundhöhle durch Einbringen einer von einer Lichtquelle aktivierbaren Substanz.The invention relates to a method for treating in particular inflammatory disease states in the oral cavity by introducing a substance which can be activated by a light source.
Stand der TechnikState of the art
Unter Photodynamische Therapie wird ein photochemisches Verfahren verstanden, das bisher vor allem in der Krebstherapie Anwendung fand. Unter diesem Begriff wird allgemein eine lichtinduzierte Inaktivierung von Zellen, Mikroorganismen oder Molekülen verstanden. Ein Wirkstoff heftet sich an die zu bekämpfenden Zellen an und wird dann durch Licht aktiviertPhotodynamic therapy is understood to mean a photochemical process which has hitherto been used primarily in cancer therapy. By this term is generally understood a light-induced inactivation of cells, microorganisms or molecules. An active substance attaches to the cells to be controlled and is then activated by light
BESTÄTIGUNGSKOPfE Eine Modifikation dieses Prinzip findet in der Bekämpfung von Mikroorganismen Anwendung - die „Antimikrobielle Photodynamische Therapie" (APT). Dabei ist das Ziel nicht die Vernichtung körpereigener (Tumor) - Zellen, sondern die gezielte Bekämpfung lokaler Infektionen, die Bekämpfung von Mikroorganismen. Das Wirkungsprinzip der APT beruht auf der selektiven Anfärbung der Mikroorganismen durch einen sogenannten Photosensitizer und der Zerstörung der Keime durch Belichtung mit einer geeigneten, auf den Photosensitizer abgestimmten Lichtquelle.confirmation head A modification of this principle is used in the control of microorganisms - the "antimicrobial photodynamic therapy" (APT) .The aim is not the destruction of the body's own (tumor) cells, but the targeted control of local infections, the fight against microorganisms The APT is based on the selective staining of the microorganisms by a so-called photosensitizer and the destruction of the germs by exposure to a suitable, matched to the photosensitizer light source.
Ein entsprechendes Verfahren ist aus der WO 01/87416 A1 bekannt. Mit Hilfe der lichtaktivierbaren Substanz, insbesondere eines Farbstoffes, werden die Mikroorganismen, sensibilisiert und/oder angefärbt und nach Bestrahlung mit Licht geeigneter Wellenlänge und Energiedichte abgetötet: Die mittels eines Bestrahlungsgeräts, insbesondere eines Lasergeräts, erzeugte Energie wird damit auf die Mikroorganismen konzentriert und die Gleichgewichtslage von Reaktionen, welche auch im nicht belichteten Zustand im „normalen" Milieu ablaufen, werden verschoben und in der Folge werden die Mikroorganismen zerstört.A corresponding method is known from WO 01/87416 A1. With the aid of the light-activatable substance, in particular a dye, the microorganisms are sensitized and / or stained and killed after irradiation with light of suitable wavelength and energy density: The energy generated by means of an irradiation device, in particular a laser device is thus concentrated on the microorganisms and the equilibrium position reactions that occur in the unexposed state in the "normal" milieu are postponed and as a result the microorganisms are destroyed.
Femer ist aus der EP 0 637 976 Bl die Verwendung einer lichtsensibilisierenden Substanz oder Verbindung bzw. eines Photosensitizers oder Photosensibilisators (PS) bei der Herstellung eines Medikamentes zur Verwendung bei der Desinfizierung oder Sterilisierung von Geweben der Mundhöhle oder einer Wunde oder Läsion in der Mundhöhle durch Zerstören von mit einer Erkrankung verbundenen Mikroben in einer periodontalen Tasche, in der Region zwischen dem Zahn und dem Zahnfleisch bekannt. Hierbei erfolgt eine Kontaktierung der Gewebe, der Wunde oder der Läsion mit dem Photosensitizer, wobei die mit der Erkrankung verbundenen Mikroben den Photosensitizer aufnehmen. Es wird eine Bestrahlung der Gewebe, der Wunde oder der Läsion mit Laserlicht bei einer durch den Photosensitizer absorbierenden Wellenlänge durchgeführt. Die Keimreduktion dieser kombinierten Farbstoff- und Laserbehandlung wird für verschiedene Keime und Photosensitizer in Form von Lösungen mit unter anderem Methylenblau und Toluidinblau beschrieben, wobei ferner der Einfluß der applizierten Energiedichte aufgezeigt wird. Als Lichtquellen werden HeNe-Laser sowie GaAs-Laser verwendet.Furthermore, EP 0 637 976 B1 discloses the use of a photosensitizing substance or compound or photosensitizer (PS) in the manufacture of a medicament for use in disinfecting or sterilizing tissues of the oral cavity or a wound or lesion in the oral cavity Destroying disease-related microbes in a periodontal pocket, known in the region between the tooth and the gums. This involves contacting the tissue, the wound or the lesion with the photosensitizer, with the microbes associated with the disease receiving the photosensitizer. Irradiation of the tissue, wound or lesion with laser light is performed at a wavelength absorbing by the photosensitizer. The germ reduction of this combined dye and laser treatment is for different germs and Photosensitizer described in the form of solutions with, inter alia, methylene blue and toluidine blue, further showing the influence of the applied energy density. The light sources used are HeNe lasers and GaAs lasers.
Aufgabetask
Aufgabe der vorliegenden Erfindung ist es, ein Verfahren der o.g. Art zu entwickeln, bei dem ein geeigneter Wirkstoff Anwendung findet, der vor allem auch nach kurzer Zeit nicht mehr nachweisbar ist.The object of the present invention is to provide a method of the above-mentioned. To develop a type in which a suitable drug is used, which is especially after a short time no longer detectable.
Lösung der AufgabeSolution of the task
Zur Lösung der Aufgabe führt, dass die Substanz den Wirkstoff Indocyaningrün enthält und das Spektrum der Lichtquelle nennenswerte Anteile im Bereich von 700 — 1.000 nm emittiert.To achieve this object, the substance contains the active ingredient indocyanine green and the spectrum of the light source emits significant proportions in the range of 700-1,000 nm.
Indocyaningrün ist ein Infrarotfarbstoff, der in der medizinischen Diagnostik verwendet und unter dem Namen IR 125 als Laserfarbstoff eingesetzt wird. Es findet als intravenöses Diagnostikum mit einem breiten Spektrum in der Herz- Kreislauf-, Mikrozirkulations- und Leberfunktionsdiagnostik Anwendung und vor allem auch bei der Messung im Auge bzw. der Netzhaut.Indocyanine Green is an infrared dye used in medical diagnostics and used under the name IR 125 as a laser dye. It is used as an intravenous diagnostic agent with a broad spectrum in the cardiovascular, microcirculation and liver function diagnostics application and especially in the measurement in the eye or the retina.
Gemäss der vorliegenden Erfindung wird nun ein völlig neues Anwendungsgebiet eröffnet, welches nicht zu erwarten war, nämlich die Verwendung zur Behandlung von insbesondere entzündlichen Krankheitszuständen in der Mundhöhle im Zusammenwirken mit einer aktivierenden Lichtquelle. Die Substanz hat den grossen Vorteil, dass sie nach ca. drei Stunden nicht mehr nachweisbar ist.According to the present invention, a completely new field of application is now opened, which was not to be expected, namely the use for the treatment of, in particular, inflammatory disease states in the oral cavity in cooperation with an activating light source. The substance has the great advantage that it is no longer detectable after about three hours.
Als Lichtquelle sollen vor allem Halbleiterlaser (Diodenlaser) oder Licht emittierende Dioden (LED's) eingesetzt werden. Die eingesetzten Lichtquellen sollen bevorzugt Licht mit einer Wellenlänge im Bereich zwischen 780-830 nm emittiert. Die Ausgangsleistung der Lichtquelle liegt bevorzugt im Bereich zwischen 50 mW und 5.000 mW. Dies ergibt eine Bestrahlungsdosis zwischen 0,5 J — 50 J bei einer Belichtungsdauer von 10s - 100s.The main source of light is semiconductor lasers (diode lasers) or light emitting diodes (LEDs). The used Light sources should preferably emit light with a wavelength in the range between 780-830 nm. The output power of the light source is preferably in the range between 50 mW and 5,000 mW. This gives an irradiation dose of between 0.5 J-50 J at an exposure time of 10s-100s.
Bei der Applikation des Lichtes soll die Lichtquelle im Bereich zwischen 1.000 — 50.000 Hz, bevorzugt im Bereich zwischen 10.000 Hz — 20.000 Hz, gepulst werden. Dabei kann die Pause zwischen zwei Pulsen länger ist als die Pulszeit sein.When applying the light, the light source should be pulsed in the range between 1,000 and 50,000 Hz, preferably in the range between 10,000 Hz and 20,000 Hz. The pause between two pulses may be longer than the pulse time.
Die Substanz wird in steriler Darreichungsform appliziert. Ferner können der Substanz weitere Inhaltsstoffe hinzugefügt werden, die entzündliche Prozesse positiv beeinflussen.The substance is administered in sterile dosage form. Furthermore, the substance can be added to other ingredients that positively influence inflammatory processes.
Als Darreichungsform bietet es sich an, dass die Substanz in Form einer Mundspüllösung eine gewisse Zeit in der Mundhöhle verbleibt und die Belichtung des Wirkstoffs mit einer Lichtquelle nach dem Ausspülen des Wirkstoffs erfolgt. Dabei erfolgt die Belichtung des Wirkstoffs über eine Vorrichtung, welche die Lichtquelle enthält und temporär (z.B. während einer Arbeitspause oder über Nacht) getragen wird. Eine weitere Möglichkeit ist das Einbringen der Wirkstofflösung über eine entsprechende Applikationsvorrichtung, wie z.B. eine Spritze in schwer zugängliche Bereiche, wie Parodontaltaschen o.a.. As a dosage form, it is advisable that the substance in the form of a mouthwash solution remains in the oral cavity for a certain time and the exposure of the active substance to a light source takes place after rinsing out the active substance. The exposure of the drug is via a device that contains the light source and is worn temporarily (e.g., during a break or overnight). Another possibility is the introduction of the drug solution via a corresponding application device, such. a syringe in hard-to-reach areas, such as periodontal pockets or similar.

Claims

Patentansprüche claims
1. Verfahren zur Behandlung von insbesondere entzündlichen Krankheitszuständen in der Mundhöhle durch Einbringen einer von einer Lichtquelle aktivierbaren Substanz,1. A method for treating, in particular, inflammatory disease states in the oral cavity by introducing a substance that can be activated by a light source,
dadurch gekennzeichnet,characterized,
dass die Substanz den Wirkstoff Indocyaningrün enthält und das Spektrum der Lichtquelle nennenswerte Anteile im Bereich von 700 — 1.000 nm emittiert.that the substance contains the active ingredient indocyanine green and the spectrum of the light source emits significant proportions in the range of 700-1,000 nm.
2. Verfahren nach Anspruch 1 , dadurch gekennzeichnet, dass als Lichtquelle Halbleiterlaser (Diodenlaser) oder Licht emittierende Dioden (LED's) eingesetzt werden.2. The method according to claim 1, characterized in that as the light source semiconductor laser (diode laser) or light-emitting diodes (LED's) are used.
3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die eingesetzten Lichtquelle Licht mit einer Wellenlänge im Bereich zwischen 780-830 nm emittiert.3. The method according to claim 1 or 2, characterized in that the light source used emits light having a wavelength in the range between 780-830 nm.
4. Verfahren nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass die Substanz den Wirkstoff Indocyaningrün in einer wässrigen Lösung enthält.4. The method according to any one of claims 1 to 3, characterized in that the substance contains the active ingredient indocyanine green in an aqueous solution.
5. Verfahren nach wenigstens einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass die Substanz in steriler Darreichungsform appliziert wird.5. The method according to at least one of claims 1 to 4, characterized in that the substance is applied in sterile dosage form.
6. Verfahren nach wenigstens einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass die Lichtquelle im Bereich zwischen 1.000 — 50.000 Hz gepulst wird. 6. The method according to at least one of claims 1 to 5, characterized in that the light source is pulsed in the range between 1,000 - 50,000 Hz.
7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, dass die Lichtquelle im Bereich zwischen 10.000 Hz — 20.000 Hz gepulst wird.7. The method according to claim 6, characterized in that the light source in the range between 10,000 Hz - 20,000 Hz is pulsed.
8. Verfahren nach Anspruch 6 oder 7, dass die Pause zwischen zwei Pulsen länger ist als die Pulszeit.8. The method of claim 6 or 7, that the pause between two pulses is longer than the pulse time.
9. Verfahren nach wenigstens einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass die Ausgangsleistung der Lichtquelle im Bereich zwischen 50 mW und 5.000 mW beträgt9. The method according to at least one of claims 1 to 8, characterized in that the output power of the light source is in the range between 50 mW and 5,000 mW
10. Verfahren nach wenigstens einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass die Bestrahlungsdosis zwischen 0,5 J — 50 J beträgt.10. The method according to at least one of claims 1 to 9, characterized in that the irradiation dose is between 0.5 J - 50 J.
11. Verfahren nach wenigstens einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass der Substanz weitere Inhaltsstoffe hinzugefügt werden, die entzündliche Prozesse positiv beeinflussen können.11. The method according to at least one of claims 1 to 10, characterized in that the substance further ingredients are added, which can positively influence inflammatory processes.
12. Verfahren nach wenigstens einem der Ansprüche 1 bis 1 1 , dadurch gekennzeichnet, dass die Substanz in Form einer Mundspüllösung eine gewisse Zeit in der Mundhöhle verbleibt und die Belichtung des Wirkstoffs mit einer Lichtquelle nach dem Ausspülen des Wirkstoffs erfolgt.12. The method according to at least one of claims 1 to 1 1, characterized in that the substance in the form of a mouthwash solution for a certain time remains in the oral cavity and the exposure of the active ingredient is carried out with a light source after rinsing the active ingredient.
13. Verfahren nach Anspruch 12, dadurch gekennzeichnet, dass die Belichtung des Wirkstoffs über eine Vorrichtung erfolgt, welche die Lichtquelle enthält und temporär (z.B. in der Arbeitspause oder über Nacht) getragen wird.A method according to claim 12, characterized in that the exposure of the active substance is effected by means of a device which contains the light source and is worn temporarily (e.g., during work break or overnight).
14. Verwendung von Indocyaningrün zur Behandlung von insbesondere entzündlichen Krankheitszuständen in der Mundhöhle, indem eine Indocyanin enthaltende Substanz in die Mundhöhle eingebracht und der Wirkstoff mit einer Lichtquelle aktiviert wird. 14. Use of indocyanine green for the treatment of, in particular, inflammatory disease states in the oral cavity by introducing an indocyanine-containing substance into the oral cavity and activating the active ingredient with a light source.
EP07711778A 2006-03-08 2007-03-05 Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity Ceased EP1993534A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006011043A DE102006011043A1 (en) 2006-03-08 2006-03-08 Method for the treatment of, in particular, inflammatory disease states in the oral cavity
PCT/EP2007/001867 WO2007101641A1 (en) 2006-03-08 2007-03-05 Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity

Publications (1)

Publication Number Publication Date
EP1993534A1 true EP1993534A1 (en) 2008-11-26

Family

ID=38121752

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07711778A Ceased EP1993534A1 (en) 2006-03-08 2007-03-05 Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity

Country Status (5)

Country Link
US (1) US20090156656A1 (en)
EP (1) EP1993534A1 (en)
CA (1) CA2645168A1 (en)
DE (1) DE102006011043A1 (en)
WO (1) WO2007101641A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011000020A1 (en) * 2011-01-03 2012-07-05 A.R.C. Laser Gmbh Active substance containing indocyanine green and / or infracyanine green
DE102011000715A1 (en) 2011-02-14 2012-08-16 Elexxion Ag Active substance for the treatment of inflammatory disease states in the oral cavity
DE102011055541A1 (en) 2011-11-21 2013-05-23 Elexxion Ag Process for the treatment of humans and / or animals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021992A1 (en) * 1992-04-30 1993-11-11 Institute Of Dental Surgery Laser treatment
DE19610348A1 (en) * 1996-03-15 1997-09-18 Pulsion Verwaltungs Gmbh & Co Treatment of tumours
US6676655B2 (en) * 1998-11-30 2004-01-13 Light Bioscience L.L.C. Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen
US6944493B2 (en) * 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
US6551346B2 (en) * 2000-05-17 2003-04-22 Kent Crossley Method and apparatus to prevent infections
US7354448B2 (en) * 2001-11-29 2008-04-08 Palomar Medical Technologies, Inc. Dental phototherapy methods and compositions
US20090285766A1 (en) * 2005-06-13 2009-11-19 National University Of Singapore Photosensitising Composition and Uses Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007101641A1 *

Also Published As

Publication number Publication date
CA2645168A1 (en) 2007-09-13
US20090156656A1 (en) 2009-06-18
WO2007101641A1 (en) 2007-09-13
DE102006011043A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
Plotino et al. Photodynamic therapy in endodontics
Trindade et al. Photodynamic therapy in endodontics: a literature review
Chiniforush et al. Can antimicrobial photodynamic therapy (aPDT) enhance the endodontic treatment?
Vohra et al. Efficacy of mechanical debridement with adjunct antimicrobial photodynamic therapy for the management of peri-implant diseases: a systematic review
Gambarini et al. In vitro evaluation of the cytotoxicity of FotoSan™ light-activated disinfection on human fibroblasts
Singh et al. Photodynamic therapy: An adjunct to conventional root canal disinfection strategies
CN113423464A (en) Method for treating biological surfaces
EP1626777B1 (en) Micro-organism-reducing device
Firmino et al. Endodontic treatment associated with photodynamic therapy: Case report
DE60033020T2 (en) DEVICE FOR TREATING TOOTH CARIES
Dave et al. Photodynamic therapy: A view through light
EP1993534A1 (en) Use of light-active indocyanine green for treating inflammatory disorders in the oral cavity
DE102007013040A1 (en) Tooth bleaching system for bleaching vital or devital tooth, has oxidizing agent and metal mixed oxide, where oxidizing agent is peroxide, and additional materials are also provided
SIVIERI-ARAUJO et al. Photodynamic therapy in Endodontics: Use of a supporting strategy to deal with endodontic infection.
EP3700461B1 (en) Hand-held device for fluorescence excitation and for irradiating microorganisms in the mouth and throat
EP2471532A2 (en) Agent containing indocyanine green and/or infracyanine green
Khurana et al. Photodynamic therapy-A ray towards periodontics
US11382977B2 (en) Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections
RU2606834C2 (en) Gel-photosensitizer for photodynamic therapy
Tapashetti et al. Photodynamic Therapy in Periodontics
Marković et al. Application of high-power diode laser and photodynamic therapy in endodontic treatment: Review of the literature
Asnaashari et al. The Effect of High-Power Lasers on Root Canal Disinfection: A Systematic Review
Bourbour et al. Effects of Antimicrobial photosensitizers of Photodynamic Therapy (PDT) to Treat Periodontitis
WO2016083239A1 (en) Anti-microbial photodynamic therapy
Khan et al. Photodynamic therapy: A targeted therapy in periodontics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090821

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELEXXION AG

DAX Request for extension of the european patent (deleted)
APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20121106